Literature DB >> 23338722

Chronic kidney disease as a coronary artery disease risk equivalent.

Alexandrios Briasoulis1, George L Bakris.   

Abstract

Chronic kidney disease (CKD) is associated with accelerated cardiovascular disease (CVD) risk and a higher CVD event rate. Substantial data from prospective cohort studies support the concept that dialysis patients as well as those with advanced stage (stages 3-5) CKD are associated with an increased risk for all-cause and cardiovascular mortality. The risk for coronary artery disease (CAD) increases exponentially with declining kidney function, i.e., stage 3 or higher CKD. Indeed, CVD accounts for more than 50 % of deaths in patients with CKD. CKD patients are more likely to die of CVD than to progress to end stage kidney disease. This increase in CV risk is commonly attributed to co-existence of numerous traditional and nontraditional risk factors for the development of CVD that frequently accompany reduced kidney function. Therefore, CKD itself is now considered an independent CVD risk factor and a coronary artery disease (CAD) equivalent for all-cause mortality. All patients at risk for CAD should be evaluated for kidney disease. Treatments used for management of established CAD might have similar benefits for patients with concomitant CKD.

Entities:  

Mesh:

Year:  2013        PMID: 23338722     DOI: 10.1007/s11886-012-0340-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  41 in total

1.  Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Authors:  Tomofumi Takaya; Seinosuke Kawashima; Masakazu Shinohara; Tomoya Yamashita; Ryuji Toh; Naoto Sasaki; Nobutaka Inoue; Ken-ichi Hirata; Mitsuhiro Yokoyama
Journal:  Atherosclerosis       Date:  2005-09-12       Impact factor: 5.162

2.  Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Brenda R Hemmelgarn
Journal:  Ann Intern Med       Date:  2011-01-04       Impact factor: 25.391

3.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn
Journal:  Lancet       Date:  2012-06-19       Impact factor: 79.321

4.  Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease.

Authors:  Shifra Sela; Revital Shurtz-Swirski; Meital Cohen-Mazor; Rafi Mazor; Judith Chezar; Galina Shapiro; Kamal Hassan; Galina Shkolnik; Ronit Geron; Batya Kristal
Journal:  J Am Soc Nephrol       Date:  2005-06-29       Impact factor: 10.121

5.  Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease.

Authors:  A E M Stinghen; S M Gonçalves; E G Martines; L S Nakao; M C Riella; C A Aita; R Pecoits-Filho
Journal:  Nephron Clin Pract       Date:  2009-01-16

6.  Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization.

Authors:  Alexandra E Ewence; Martin Bootman; H Llewelyn Roderick; Jeremy N Skepper; Geraldine McCarthy; Matthias Epple; Markus Neumann; Catherine M Shanahan; Diane Proudfoot
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

7.  The Framingham predictive instrument in chronic kidney disease.

Authors:  Daniel E Weiner; Hocine Tighiouart; Essam F Elsayed; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2007-07-02       Impact factor: 24.094

Review 8.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

9.  Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study.

Authors:  Rajat Deo; Christina L Wassel Fyr; Linda F Fried; Anne B Newman; Tamara B Harris; Sara Angleman; Christie Green; Stephen B Kritchevsky; Glenn M Chertow; Steven R Cummings; Michael G Shlipak
Journal:  Am Heart J       Date:  2007-10-24       Impact factor: 4.749

Review 10.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.

Authors:  Bakhtawar K Mahmoodi; Kunihiro Matsushita; Mark Woodward; Peter J Blankestijn; Massimo Cirillo; Takayoshi Ohkubo; Peter Rossing; Mark J Sarnak; Bénédicte Stengel; Kazumasa Yamagishi; Kentaro Yamashita; Luxia Zhang; Josef Coresh; Paul E de Jong; Brad C Astor
Journal:  Lancet       Date:  2012-09-24       Impact factor: 79.321

View more
  46 in total

Review 1.  MR imaging of the coronary vasculature: imaging the lumen, wall, and beyond.

Authors:  Kai Lin; James C Carr
Journal:  Radiol Clin North Am       Date:  2015-03       Impact factor: 2.303

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

3.  Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis.

Authors:  Carrie B Wiese; Jianyong Zhong; Zhi-Qi Xu; Youmin Zhang; Marisol A Ramirez Solano; Wanying Zhu; MacRae F Linton; Quanhu Sheng; Valentina Kon; Kasey C Vickers
Journal:  Atherosclerosis       Date:  2019-01-30       Impact factor: 5.162

4.  Aldosterone, Renin, Cardiovascular Events, and All-Cause Mortality Among African Americans: The Jackson Heart Study.

Authors:  Joshua J Joseph; Justin B Echouffo-Tcheugui; Rita R Kalyani; Hsin-Chieh Yeh; Alain G Bertoni; Valery S Effoe; Ramon Casanova; Mario Sims; Wen-Chih Wu; Gary S Wand; Adolfo Correa; Sherita H Golden
Journal:  JACC Heart Fail       Date:  2017-08-16       Impact factor: 12.035

5.  Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.

Authors:  BinBin Zheng-Lin; Alberto Ortiz
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 6.  The myth of 'stable' coronary artery disease.

Authors:  Keith A A Fox; Marco Metra; João Morais; Dan Atar
Journal:  Nat Rev Cardiol       Date:  2019-07-29       Impact factor: 32.419

7.  Increased arterial stiffness after coronary artery revascularization correlates with serious coronary artery lesions and poor clinical outcomes in patients with chronic kidney disease.

Authors:  Zhengbin Zhu; Zijun Yan; Lin Zhang; Run Du; Jinzhou Zhu; Junli Zuo; Shaoli Chu; Weifeng Shen; Ruiyan Zhang
Journal:  Cardiorenal Med       Date:  2014-12-10       Impact factor: 2.041

8.  Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup.

Authors:  Arun Kumar Subbiah; Yogesh K Chhabra; Sandeep Mahajan
Journal:  Heart Asia       Date:  2016-11-07

9.  Stress SPECT Myocardial Perfusion Imaging in End-Stage Renal Disease.

Authors:  Yasmeen Golzar; Rami Doukky
Journal:  Curr Cardiovasc Imaging Rep       Date:  2017-03-18

10.  Correlation of coronary plaque characteristics and obstructive stenosis with chronic kidney disease by coronary CT angiography.

Authors:  Chengming Wang; Guanxun Cheng; Yibo Duanmu; Yi Zhu; Lu Xu
Journal:  Cardiovasc Diagn Ther       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.